These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 26398681)

  • 1. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
    Rivera-Nieves J
    Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Panés J; Salas A
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
    Lamb CA; O'Byrne S; Keir ME; Butcher EC
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-integrin therapy for inflammatory bowel disease.
    Park SC; Jeen YT
    World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Sands BE
    Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
    Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Bamias G; Dulai PS; Boland BS; Sandborn WJ; Patel DR; Rivera-Nieves J
    Inflamm Bowel Dis; 2019 Jan; 25(2):270-282. PubMed ID: 30165490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
    Zundler S; Becker E; Schulze LL; Neurath MF
    Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
    Jovani M; Danese S
    Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Therapeutics for IBD.
    Löwenberg M; D'Haens G
    Curr Gastroenterol Rep; 2015 Jun; 17(6):21. PubMed ID: 26031830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
    Saruta M; Papadakis KA
    Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of αEβ7 integrin suppresses accumulation of CD8
    Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
    Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.
    Krupka N; Baumgart DC
    Drug Des Devel Ther; 2015; 9():147-54. PubMed ID: 25552903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update.
    Cesarini M; Fiorino G
    Expert Rev Clin Immunol; 2013 Apr; 9(4):301-6. PubMed ID: 23557266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.
    Thomas S; Baumgart DC
    Inflammopharmacology; 2012 Feb; 20(1):1-18. PubMed ID: 22205271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.
    Reinisch W; Hung K; Hassan-Zahraee M; Cataldi F
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S669-S677. PubMed ID: 29757363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease.
    Tang MT; Keir ME; Erickson R; Stefanich EG; Fuh FK; Ramirez-Montagut T; McBride JM; Danilenko DM
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1440-1452. PubMed ID: 29601644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
    McLean LP; Cross RK
    Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.